Cargando…

The Value of SSTR2 Receptor-Targeted PET/CT in Proton Irradiation of Grade I Meningioma

SIMPLE SUMMARY: Meningiomas are the most frequent tumors of the central nervous system. Their treatment outcomes depend on the histologic grade. Grade I tumors, even bulky and unresectable, are well curable with radiation; therefore, most precise and conservative techniques such as proton therapy ar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pelak, Maciej J., Flechl, Birgit, Mumot, Marta, Galalae, Razvan, Tubin, Slavisa, Hug, Eugen, Lütgendorf-Caucig, Carola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8469658/ https://www.ncbi.nlm.nih.gov/pubmed/34572933 http://dx.doi.org/10.3390/cancers13184707

Ejemplares similares

Normofractionated and moderately hypofractionated proton therapy: comparison of acute toxicity and early quality of life outcomes
por: Pelak, Maciej J., et al.
Publicado: (2022)

Proton or Carbon Ion Therapy for Skull Base Chordoma: Rationale and First Analysis of a Mono-Institutional Experience
por: Tubin, Slavisa, et al.
Publicado: (2023)

Impact of SSTR PET on Inter-Observer Variability of Target Delineation of Meningioma and the Possibility of Using Threshold-Based Segmentations in Radiation Oncology
por: Kriwanek, Florian, et al.
Publicado: (2022)

Evaluation of the inter- and intrafraction displacement for head patients treated at the particle therapy centre MedAustron based on the comparison of different commercial immobilisation devices
por: Zechner, Andrea, et al.
Publicado: (2021)

Novel Carbon Ion and Proton Partial Irradiation of Recurrent Unresectable Bulky Tumors (Particle-PATHY): Early Indication of Effectiveness and Safety
por: Tubin, Slavisa, et al.
Publicado: (2022)

Clinical Significance of Somatostatin Receptor (SSTR) 2 in Meningioma
por: Wu, Wei, et al.
Publicado: (2020)

The Prognostic Value of Pretreatment Gallium-68 DOTATATE Positron Emission Tomography/Computed Tomography in Irradiated Non-benign Meningioma
por: Pelak, Maciej J., et al.
Publicado: (2019)

Differences in the expression of SSTR1–5 in meningiomas and its therapeutic potential
por: Behling, Felix, et al.
Publicado: (2021)

The immunohistochemical expression of SSTR2A is an independent prognostic factor in meningioma
por: Fodi, Christina, et al.
Publicado: (2021)

Time-synchronized immune-guided SBRT partial bulky tumor irradiation targeting hypoxic segment while sparing the peritumoral immune microenvironment
por: Tubin, Slavisa, et al.
Publicado: (2019)

Correction to: The immunohistochemical expression of SSTR2A is an independent prognostic factor in meningioma
por: Fodi, Christina, et al.
Publicado: (2022)

An MRI sequence independent convolutional neural network for synthetic head CT generation in proton therapy
por: Zimmermann, Lukas, et al.
Publicado: (2021)

Guiding Treatment Choices for Elderly Patients with Glioblastoma by a Comprehensive Geriatric Assessment
por: Lütgendorf-Caucig, Carola, et al.
Publicado: (2020)

Novel stereotactic body radiation therapy (SBRT)-based partial tumor irradiation targeting hypoxic segment of bulky tumors (SBRT-PATHY): improvement of the radiotherapy outcome by exploiting the bystander and abscopal effects
por: Tubin, Slavisa, et al.
Publicado: (2019)

Value of SSTR2A and Claudin - 1 in Differentiating Meningioma from Schwannoma and Hemangiopericytoma
por: Anis, Shady E., et al.
Publicado: (2018)

SSTR-2 as a potential tumour-specific marker for fluorescence-guided meningioma surgery
por: Dijkstra, B. M., et al.
Publicado: (2018)

Validation of the SSTR-RADS 1.0 for the structured interpretation of SSTR-PET/CT and treatment planning in neuroendocrine tumor (NET) patients
por: Grawe, Freba, et al.
Publicado: (2023)

Shifting the Immune-Suppressive to Predominant Immune-Stimulatory Radiation Effects by SBRT-PArtial Tumor Irradiation Targeting HYpoxic Segment (SBRT-PATHY)
por: Tubin, Slavisa, et al.
Publicado: (2020)

Next-generation PET/CT imaging in meningioma—first clinical experiences using the novel SSTR-targeting peptide [(18)F]SiTATE
por: Unterrainer, Marcus, et al.
Publicado: (2023)

mRNA expression of somatostatin receptor subtypes SSTR-2, SSTR-3, and SSTR-5 and its significance in pancreatic cancer
por: Shahbaz, Muhammad, et al.
Publicado: (2015)

Correction to: Next‑generation PET/CT imaging in meningioma—first clinical experiences using the novel SSTR‑targeting peptide [(18)F]SiTATE
por: Unterrainer, Marcus, et al.
Publicado: (2023)

A Review of Particle Therapy for Skull Base Tumors: Modern Considerations and Future Directions
por: Hug, Eugen B., et al.
Publicado: (2021)

A Definitive IMRT-SIB with Concomitant Chemotherapy for Synchronous Locally Advanced Anal Canal Cancer and Prostate Cancer
por: Slavisa, Tubin, et al.
Publicado: (2018)

The effect of strength and endurance training on SSTR2 and SSTR5 in patients with colorectal cancer
por: Zanjani, Farhad Safari, et al.
Publicado: (2019)

Vienna Summer School on Oncology: how to teach clinical decision making in a multidisciplinary environment
por: Lütgendorf-Caucig, Carola, et al.
Publicado: (2017)

Expression of Somatostatin Receptor Subtypes (SSTR-1–SSTR-5) in Pediatric Hematological and Oncological Disorders
por: Harda, Kristof, et al.
Publicado: (2020)

Coexpression of human somatostatin receptor-2 (SSTR2) and SSTR3 modulates antiproliferative signaling and apoptosis
por: War, Sajad A, et al.
Publicado: (2012)

Hypofractionated high-energy proton-beam irradiation is an alternative treatment for WHO grade I meningiomas
por: Vlachogiannis, Pavlos, et al.
Publicado: (2017)

Cardiac metastases from neuroendocrine neoplasms: complementary role of SSTR PET/CT and cardiac MRI
por: Arnfield, Evyn G., et al.
Publicado: (2023)

Comparing the use of radiolabeled SSTR agonists and an SSTR antagonist in breast cancer: does the model choice influence the outcome?
por: Dalm, Simone U., et al.
Publicado: (2017)

Grading Meningioma: A Comparative Study of Thallium-SPECT and FDG-PET
por: Okuchi, Sachi, et al.
Publicado: (2015)

Favorable SSTR subtype selectivity of SiTATE: new momentum for clinical [(18)F]SiTATE PET
por: Wängler, Carmen, et al.
Publicado: (2022)

Quantitative SSTR-PET/CT for predicting response and survival outcomes in patients with pancreatic neuroendocrine tumors receiving CAPTEM
por: Ingenerf, Maria, et al.
Publicado: (2023)

Biology of NSCLC: Interplay between Cancer Cells, Radiation and Tumor Immune Microenvironment
por: Tubin, Slavisa, et al.
Publicado: (2021)

Distinguishing grade I meningioma from higher grade meningiomas without biopsy
por: Varlotto, John, et al.
Publicado: (2015)

Molecular simulations of SSTR2 dynamics and interaction with ligands
por: Gervasoni, Silvia, et al.
Publicado: (2023)

Clinical Importance of Somatostatin Receptor 2 (SSTR2) and Somatostatin Receptor 5 (SSTR5) Expression in Thyrotropin-Producing Pituitary Adenoma (TSHoma)
por: Yu, Benxia, et al.
Publicado: (2017)

Retracted: Clinical Importance of Somatostatin Receptor 2 (SSTR2) and Somatostatin Receptor 5 (SSTR5) Expression in Thyrotropin-Producing Pituitary Adenoma (TSHoma)
por: Song, Hao, et al.
Publicado: (2018)

SPECT and PET Imaging of Meningiomas
por: Valotassiou, Varvara, et al.
Publicado: (2012)

Prediction of Meningioma WHO Grade Using PET Findings: A Systematic Review and Meta‐Analysis
por: Slot, K. Mariam, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_79pdkkra8ivmp7uc65unm2viqr